Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities
Blood Cancer Journal, 2020 In marked contrast to multiple myeloma, racial/ethnic minorities are underrepresented in publications of systemic light-chain (AL) amyloidosis. The impact of race/ethnicity is therefore lacking in the narrative of this disease.
Andrew Staron +4 more
semanticscholar +1 more source
Virtual birefringence imaging and histological staining of amyloid deposits in label-free tissue using autofluorescence microscopy and deep learning [PDF]
Nature Communications (2024)Systemic amyloidosis is a group of diseases characterized by the deposition of misfolded proteins in various organs and tissues, leading to progressive organ dysfunction and failure. Congo red stain is the gold standard chemical stain for the visualization of amyloid deposits in tissue sections, as it forms complexes with the misfolded proteins and ...
arxiv +1 more source
AL amyloidosis: from molecular mechanisms to targeted therapies.
Hematology. American Society of Hematology. Education Program, 2017 Systemic amyloidosis is caused by misfolding and extracellular deposition of circulating proteins as amyloid fibrils, resulting in the dysfunction of vital organs. The most common systemic amyloidosis, light-chain (AL) amyloidosis, is caused by misfolded
G. Merlini
semanticscholar +1 more source
AL amyloidosis: advances in diagnostics and treatment.
Nephrology, Dialysis and Transplantation, 2018 AL amyloidosis (light chain; previously also called primary amyloidosis) is a systemic disease characterized by an amyloid deposition process affecting many organs, and which still has unsatisfactory survival of patients.
R. Ryšavá
semanticscholar +1 more source
Bilateral Chronic Subdural Nontraumatic Hematoma in a Woman Affected by AL Amyloidosis
Journal of Neurological Surgery Reports, 2015 Chronic subdural hematoma (CSDH) is a condition frequently seen in neurosurgical practice, especially among the elderly. It is often preceded by head injury, even a trivial trauma. Light chain (AL) amyloidosis is a disorder involving extracellular tissue
M. Luongo, M. Grassi, U. Godano
doaj +1 more source
Current treatment of AL amyloidosis
Haematologica, 2009 Several effective chemotherapy regimens have been developed during the last decade significantly improving the outlook of patients with AL amyloidosis. Drs. Palladini and Merlini describe our current knowledge in the field and examine future perspectives. See related article on page 1094.
PALLADINI, GIOVANNI, MERLINI, GIAMPAOLO
openaire +4 more sources
Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients [PDF]
, 1998 Raymond L. Comenzo +13 more
openalex +1 more source
Incidence and survival in non-hereditary amyloidosis in Sweden
BMC Public Health, 2012 Background Amyloidosis is a heterogeneous disease caused by deposition of amyloid fibrils in organs and thereby interfering with physiological functions.
Hemminki Kari +4 more
doaj +1 more source
Multimodal Fusion of Echocardiography and Electronic Health Records for the Detection of Cardiac Amyloidosis [PDF]
arXivCardiac amyloidosis, a rare and highly morbid condition, presents significant challenges for detection through echocardiography. Recently, there has been a surge in proposing machine-learning algorithms to identify cardiac amyloidosis, with the majority being imaging-based deep-learning approaches that require extensive data.
arxiv
Structural relationship of κ-type light chains with AL amyloidosis: multiple deletions found in a VκIV protein [PDF]
, 1999 M A Alim +7 more
openalex +1 more source